Thomas Hutson, DO, PharmD, discusses key takeaways from the phase 3 CLEAR trial evaluating lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback